Rapid Micro Biosystems (RPID) Common Equity (2020 - 2026)

Rapid Micro Biosystems' Common Equity history runs 7 years deep, the most recent figure standing at $20.4 million for Q1 2026.

• In Q1 2026, Common Equity fell 68.85% year-over-year to $20.4 million; the TTM figure through Mar 2026 stood at $20.4 million (down 68.85% YoY), while the FY2025 annual figure was $33.2 million, down 55.93% from the prior year.
• Common Equity came in at $20.4 million for Q1 2026 at Rapid Micro Biosystems, down from $33.2 million in the prior quarter.
• In the past five years, Common Equity ranged from a high of $207.1 million in Q1 2022 to a low of $20.4 million in Q1 2026.
• A 5-year average of $109.5 million and a median of $105.9 million in 2024 frame the typical range for Common Equity.
• Across the five-year window, Common Equity soared 237.09% in 2022 and tumbled 68.85% in 2026, its largest moves.
• Rapid Micro Biosystems' Common Equity stood at $164.2 million in 2022, then declined by 28.13% to $118.0 million in 2023, then tumbled by 36.14% to $75.4 million in 2024, then plunged by 55.93% to $33.2 million in 2025, then sank by 38.57% to $20.4 million in 2026.
• According to Business Quant data, Common Equity over the past three periods registered $20.4 million, $33.2 million, and $44.3 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison